Citations (66)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Shosaku Nomura, Akira Shouzu, Takehito Taniura, Yoshinori Okuda, Seitaro Omoto, Masahiko Suzuki, Tomoki Ito & Nagaoki Toyoda. (2023) Effects of Tofogliflozin and Anagliptin Alone or in Combination on Glucose Metabolism and Atherosclerosis-Related Markers in Patients with Type 2 Diabetes Mellitus. Clinical Pharmacology: Advances and Applications 15, pages 41-55.
Read now
Read now
Kohei Kaku, Yayoi Nakayama, Junko Yabuuchi, Yusuke Naito & Keizo Kanasaki. (2023) Safety and effectiveness of empagliflozin in clinical practice as monotherapy or with other glucose-lowering drugs in Japanese patients with type 2 diabetes: subgroup analysis of a 3-year post-marketing surveillance study. Expert Opinion on Drug Safety 22:9, pages 819-832.
Read now
Read now
Masahiro Takihata & Yasuo Terauchi. (2019) The efficacy and safety of luseogliflozin and sitagliptin depending on the sequence of administration in patients with type 2 diabetes mellitus: a randomized controlled pilot study. Expert Opinion on Pharmacotherapy 20:17, pages 2185-2194.
Read now
Read now
Genya Aharon-Hananel & Itamar Raz. (2019) An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes. Expert Opinion on Pharmacotherapy 20:7, pages 781-790.
Read now
Read now
Yaowen Wang, Xueting Hu, Xueying Liu & Zengqi Wang. (2016) An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients. Therapeutics and Clinical Risk Management 12, pages 1113-1131.
Read now
Read now
Kalliopi Pafili, Efstratios Maltezos & Nikolaos Papanas. (2016) Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 12:11, pages 1367-1380.
Read now
Read now
Hiroyuki Ito, Masahiro Shinozaki, Shinya Nishio & Mariko Abe. (2016) SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan. Expert Opinion on Pharmacotherapy 17:15, pages 2073-2084.
Read now
Read now
Hiroshi Maegawa, Kazuyuki Tobe, Hiromi Tabuchi & Ichiro Nakamura. (2016) Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice. Expert Opinion on Pharmacotherapy 17:15, pages 1985-1994.
Read now
Read now
K. Pafili, E. Maltezos & N. Papanas. (2016) The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes. Expert Opinion on Investigational Drugs 25:10, pages 1133-1152.
Read now
Read now
Awadhesh Kumar Singh & Ritu Singh. (2016) Combination therapy of sodium–glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences. Expert Review of Clinical Pharmacology 9:2, pages 229-240.
Read now
Read now
Shuji Kinoshita & Kazuoki Kondo. (2015) Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers. Expert Opinion on Drug Metabolism & Toxicology 11:1, pages 7-14.
Read now
Read now
Kalliopi Pafili & Nikolaos Papanas. (2014) Tofogliflozin: the road goes ever on. Expert Opinion on Pharmacotherapy 15:9, pages 1197-1201.
Read now
Read now
Articles from other publishers (54)
Toshinari Takamura, Kohei Kaku, Akihiro Yoshida, Hiromi Kusakabe, Hiroyuki Nakamura & Hideki Suganami. (2023) Reductions in liver enzymes are associated with anti‐hyperglycaemic and anti‐obesity effects of tofogliflozin in people with type 2 diabetes: Post‐hoc analyses. Endocrinology, Diabetes & Metabolism.
Crossref
Crossref
Serena Perrone, Francesco Messa, Luigino Troisi & Antonio Salomone. (2023) N-, O- and S-Heterocycles Synthesis in Deep Eutectic Solvents. Molecules 28:8, pages 3459.
Crossref
Crossref
Youn Huh & Young Sik Kim. (2022) Predictors for successful weight reduction during treatment with Dapagliflozin among patients with type 2 diabetes mellitus in primary care. BMC Primary Care 23:1.
Crossref
Crossref
Yasuhiro Matsubayashi, Alkihiro Yoshida, Hideki Suganami, Momoko Oe, Takaaki Sato, Yuta Yaguchi, Kazuya Fujihara, Takaho Yamada, Shiro Tanaka, Kohei Kaku & Hirohito Sone. (2022)
Predictors of haemoglobin levels and of changes in these levels, focusing on anaemia and polycythaemia after administration of the
sodium‐glucose cotransporter‐2
inhibitor tofogliflozin
. Diabetes, Obesity and Metabolism 24:12, pages 2469-2473.
Crossref
Crossref
Maciej Spiegel & Zbigniew Sroka. (2022) Natural dihydroisobenzofuran derivatives as a template for promising radical scavengers: theoretical insights into structure–activity relationships, thermochemistry and kinetics. Theoretical Chemistry Accounts 141:11.
Crossref
Crossref
Xin Cao, Xiaojing Du, Heng Jiao, Quanlin An, Ruoxue Chen, Pengfei Fang, Jing Wang & Biao Yu. (2022) Carbohydrate-based drugs launched during 2000−2021. Acta Pharmaceutica Sinica B 12:10, pages 3783-3821.
Crossref
Crossref
Hiroshi Takahashi, Yuka Suganuma, Takayuki Ohno & Rimei Nishimura. (2022) Trends in clinical characteristics and factors associated with initial prescription of SGLT2 inhibitors in Japanese patients with type 2 diabetes mellitus. Diabetology International 13:4, pages 606-614.
Crossref
Crossref
Rune E. Kuhre, Carolyn F. Deacon, Nicolai J. Wewer Albrechtsen & Jens J. Holst. (2021) Do sodium‐glucose co‐transporter‐2 inhibitors increase plasma glucagon by direct actions on the alpha cell? And does the increase matter for the associated increase in endogenous glucose production?. Diabetes, Obesity and Metabolism 23:9, pages 2009-2019.
Crossref
Crossref
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Keiichi Torimoto, Yutaka Umayahara, Hideaki Kaneto, Takeshi Osonoi, Tsunehiko Yamamoto, Nobuichi Kuribayashi, Kazuhisa Maeda, Hiroki Yokoyama, Keisuke Kosugi, Kentaro Ohtoshi, Isao Hayashi, Satoru Sumitani, Mamiko Tsugawa, Kayoko Ryomoto, Hideki Taki, Tadashi Nakamura, Satoshi Kawashima, Yasunori Sato, Hirotaka Watada, Iichiro Shimomura, I. Hayashi, M. Tsugawa, H. Yokoyama, H. Yoshii, K. Komiyama, T. Mita, T. Shimizu, T. Yamamoto, S. Kawashima, T. Nakamura, S. Kamei, T. Kinoshita, M. Shimoda, K. Maeda, K. Kosugi, H. Yoshii, H. Ishida, T. Osonoi, M. Saito, A. Tamazawa, S. Sumitani, N. Fujiki, Y. Fujita, S. Shimizu, Y. Umayahara, K. Kato, Y. Irie, R. Kataoka, T. Yasuda, Y. Kiyohara, M. Ohashi, K. Ryomoto, Y. Takahi, Y. Fujishima, Y. Fujita, A. Fukuhara, K. Fukui, Y. Hosokawa, A. Imagawa, H. Iwahashi, K. Mukai, N. Katakami, T. Katsura, D. Kawamori, T. Kimura, S. Kobayashi, J. Kozawa, F. Kubo, N. Maeda, T. Matsuoka, K. Miyashita, S. Nakata, H. Ninomiya, H. Nishizawa, Y. Okuno, M. Otsuki, F. Sakamoto, S. Sasaki, I. Sato, N. Shimo, I. Shimomura, M. Takahara, T. Takano, A. Tokunaga, S. Uno, M. Yamaoka, S. Yoneda, K. Ohtoshi, T. Shiraiwa, M. Hajime, K. Koikawa, F. Kuno, A. Kurozumi, K. Matsushita, M. Narisawa, K. Tanaka, K. Sugai, Y. Okada & K. Torimoto. (2021) The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus. Diabetes Therapy 12:9, pages 2499-2515.
Crossref
Crossref
Yasuhiro Matsubayashi, Akihiro Yoshida, Hideki Suganami, Momoko Oe, Takaaki Sato, Yuta Yaguchi, Kazuya Fujihara, Takaho Yamada, Shiro Tanaka, Kohei Kaku & Hirohito Sone. (2021) Association of estimated plasma volume and weight loss after long‐term administration and subsequent discontinuation of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin. Diabetes, Obesity and Metabolism 23:7, pages 1660-1665.
Crossref
Crossref
Simon Buatois, Sebastian Ueckert, Nicolas Frey, Sylvie Retout & France Mentré. (2021)
cLRT‐Mod
: An efficient methodology for pharmacometric model‐based analysis of longitudinal phase
II
dose finding studies under model uncertainty
. Statistics in Medicine 40:10, pages 2435-2451.
Crossref
Crossref
Donald J. AbrahamAna R. Jesus, Bryce A. Harrison & Timothy M. Dore. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
30
.
Kazunori Utsunomiya, Ryusuke Koshida, Seigo Kakiuchi, Masayuki Senda, Shoko Fujii, Yuji Kurihara, Ryoji Gunji & Kohei Kaku. (2020) Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real‐world clinical practice: Results of a 36‐month post‐marketing surveillance study (J‐STEP/LT). Journal of Diabetes Investigation 12:2, pages 184-199.
Crossref
Crossref
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Keiichi Torimoto, Yutaka Umayahara, Hideaki Kaneto, Takeshi Osonoi, Tsunehiko Yamamoto, Nobuichi Kuribayashi, Kazuhisa Maeda, Hiroki Yokoyama, Keisuke Kosugi, Kentaro Ohtoshi, Isao Hayashi, Satoru Sumitani, Mamiko Tsugawa, Kayoko Ryomoto, Hideki Taki, Tadashi Nakamura, Satoshi Kawashima, Yasunori Sato, Hirotaka Watada & Iichiro Shimomura. (2020) Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study. Cardiovascular Diabetology 19:1.
Crossref
Crossref
Anirudh Manoj, Subham Das, Anu Kunnath Ramachandran, Angel T Alex & Alex Joseph. (2020) SGLT2 inhibitors, an accomplished development in field of medicinal chemistry: an extensive review. Future Medicinal Chemistry 12:21, pages 1961-1990.
Crossref
Crossref
Haruki Yamada, Hiromasa Ohira, Fumiaki Ikegami, Koichi Nakamura, Atsushi Takahashi, Kazumichi Abe, Akihiro Inano, Sumire Shimada, Kumiko Miyata, Tomohisa Saito, Yasuhiro Ohba, Kimio Terao & Akihiro Ohnishi. (2020) Effects of Child-Pugh B Cirrhosis on Pharmacokinetics of
Tofogliflozin, a New Sodium-Glucose Co-Transporter (SGLT2)
Inhibitor. Drug Research 70:09, pages 401-409.
Crossref
Crossref
T. Nojima, Y. Matsubayashi, A. Yoshida, H. Suganami, T. Abe, M. Ishizawa, K. Fujihara, S. Tanaka, K. Kaku & H. Sone. (2020) Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance. Diabetic Medicine 37:8, pages 1316-1325.
Crossref
Crossref
Kazunori Utsunomiya, Seigo Kakiuchi, Masayuki Senda, Shoko Fujii, Yuji Kurihara, Ryoji Gunji, Ryusuke Koshida, Hiroyuki Kameda, Masahiro Tamura & Kohei Kaku. (2020) Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24‐month interim analysis of a long‐term post‐marketing study (J‐STEP/LT). Journal of Diabetes Investigation 11:4, pages 906-916.
Crossref
Crossref
Yasuhiro Matsubayashi, Akihiro Yoshida, Hideki Suganami, Taeko Osawa, Kazuo Furukawa, Hiroshi Suzuki, Kazuya Fujihara, Shiro Tanaka, Kohei Kaku & Hirohito Sone. (2020) Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/glucose‐cotransporter 2 inhibitor tofogliflozin. Diabetes, Obesity and Metabolism 22:6, pages 947-956.
Crossref
Crossref
Mengdie Hu, Xiaoling Cai, Wenjia Yang, Simin Zhang, Lin Nie & Linong Ji. (2020) Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon‐Like Peptide‐1 Receptor Agonist and Sodium‐Glucose Cotransporter‐2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta‐Analysis. Journal of the American Heart Association 9:7.
Crossref
Crossref
Kohei Kaku, Yusuke Naito, Masayuki Senda, Yuji Kurihara, Ryoji Gunji, Seigo Kakiuchi & Kazunori Utsunomiya. (2019) Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post‐marketing study (J‐STEP/EL Study). Journal of Diabetes Investigation 11:2, pages 405-416.
Crossref
Crossref
Yuichi Sato, Kiyohide Nunoi, Kohei Kaku, Akihiro Yoshida & Hideki Suganami. (2019) Basal insulin secretion capacity predicts the initial response and maximum levels of beta‐hydroxybutyrate during therapy with the sodium‐glucose co‐transporter‐2 inhibitor tofogliflozin, in relation to weight loss. Diabetes, Obesity and Metabolism 22:2, pages 222-230.
Crossref
Crossref
Kazunori Utsunomiya, Masayuki Senda, Seigo Kakiuchi, Hiroyuki Kameda, Masahiro Tamura, Yuji Kurihara, Ryoji Gunji, Shoko Fujii & Kohei Kaku. (2019) Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real‐world practice: Results of 12‐month interim analysis of a long‐term post‐marketing surveillance study (J‐STEP/LT). Journal of Diabetes Investigation 11:1, pages 132-141.
Crossref
Crossref
Yuichiro Ito, James Van Schyndle, Takuya Nishimura, Toshifumi Sugitani & Tomomi Kimura. (2019) Drug Utilization Patterns in Patients with Diabetes Initiating Sodium Glucose Co-Transporter-2 Inhibitors (SGLT2i) in Japan: A Multi-Database Study (2014–2017). Diabetes Therapy 10:6, pages 2233-2249.
Crossref
Crossref
Yuichiro Ito, James Van Schyndle, Takuya Nishimura, Toshifumi Sugitani & Tomomi Kimura. (2019) Real-World Effectiveness of Sodium Glucose Co-Transporter-2 Inhibitors in Japanese Patients with Diabetes Mellitus. Diabetes Therapy 10:6, pages 2219-2231.
Crossref
Crossref
Yasuo Terauchi, Hisataka Fujiwara, Yuji Kurihara, Hideki Suganami, Masahiro Tamura, Masayuki Senda, Ryoji Gunji & Kohei Kaku. (2019) Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study. Journal of Diabetes Investigation 10:6, pages 1518-1526.
Crossref
Crossref
Akihiro Yoshida, Yasuhiro Matsubayashi, Toshiaki Nojima, Hideki Suganami, Takahiro Abe, Masahiro Ishizawa, Kazuya Fujihara, Shiro Tanaka, Kohei Kaku & Hirohito Sone. (2019) Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin. The Journal of Clinical Endocrinology & Metabolism 104:9, pages 3647-3660.
Crossref
Crossref
Kazunori Utsunomiya, Masayuki Senda, Seigo Kakiuchi, Hiroyuki Kameda, Masahiro Tamura, Yuji Kurihara, Ryoji Gunji, Shoko Fujii, Hisataka Fujiwara & Kohei Kaku. (2019) Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real‐world clinical practice: Results of 3‐month interim analysis of a long‐term post‐marketing surveillance study (J‐STEP/LT). Journal of Diabetes Investigation 10:5, pages 1272-1283.
Crossref
Crossref
Kiyohide Nunoi, Yuichi Sato, Kohei Kaku, Akihiro Yoshida & Hideki Suganami. (2019) Renal effects of a sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status. Diabetes, Obesity and Metabolism 21:7, pages 1715-1724.
Crossref
Crossref
Kazuo Kobayashi, Masao Toyoda & Nobuo Hatori. (2019) Clinical comparison of tofogliflozin and empagliflozin based on an analysis of 24-h accumulated urine in Japanese patients with type 2 diabetes mellitus. Obesity Medicine 14, pages 100088.
Crossref
Crossref
Jennifer R Donnan, Catherine A Grandy, Eugene Chibrikov, Carlo A Marra, Kris Aubrey-Bassler, Karissa Johnston, Michelle Swab, Jenna Hache, Daniel Curnew, Hai Nguyen & John-Michael Gamble. (2019) Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ Open 9:1, pages e022577.
Crossref
Crossref
Toshihiro Higashikawa, Tomohiko Ito, Takurou Mizuno, Keiichirou Ishigami, Masaru Kohori, Kunihiro Mae, Ryusho Sangen, Daisuke Usuda, Atsushi Saito, Masaharu Iguchi, Yuji Kasamaki, Akihiro Fukuda, Hitoshi Saito, Tsugiyasu Kanda & Masashi Okuro. (2018) The effects of 12-month administration of tofogliflozin on electrolytes and dehydration in mainly elderly Japanese patients with type 2 diabetes mellitus. Journal of International Medical Research 46:12, pages 5117-5126.
Crossref
Crossref
Jennifer R. Donnan, Catherine A. Grandy, Eugene Chibrikov, Carlo Marra PharmD, Kris Aubrey-Bassler, Karissa Johnston, Michelle Swab, Jenna Hache, Daniel Curnew, Hai Nguyen & John-Michael Gamble. (2018) Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials. CMAJ Open 6:4, pages E594-E602.
Crossref
Crossref
Hisamitsu Ishihara, Motonobu Anai, Hiroaki Seino, Toru Kitazawa, Hiroshi Ohashi, Masumi Ai, Masahiro Inoue, Midori Fujishiro, Takeshi Inazawa, Hisamoto Kuroda & Masayo Yamada. (2018) Rationale and Design of the STOP-OB Study for Evaluating the Effects of Tofogliflozin and Glimepiride on Fat Deposition in Type 2 Diabetes Patients Treated with Metformin/DPP-4 Inhibitor Dual Therapy. Diabetes Therapy 9:5, pages 2117-2125.
Crossref
Crossref
Tomoe Kinoshita, Masashi Shimoda, Junpei Sanada, Yoshiro Fushimi, Yurie Hirata, Shintaro Irie, Atsushi Obata, Tomohiko Kimura, Hidenori Hirukawa, Kenji Kohara, Fuminori Tatsumi, Shinji Kamei, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku & Hideaki Kaneto. (2018) There is a Close Association Between the Recovery of Liver Injury and Glycemic Control after SGLT2 Inhibitor Treatment in Japanese Subjects with Type 2 Diabetes: A Retrospective Clinical Study. Diabetes Therapy 9:4, pages 1569-1580.
Crossref
Crossref
Kazuyuki Tobe, Hideki Suganami & Kohei Kaku. (2018) Sodium-glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline. Journal of Diabetes Investigation 9:4, pages 862-869.
Crossref
Crossref
Seigo Sugiyama, Hideaki Jinnouchi, Noboru Kurinami, Kunio Hieshima, Akira Yoshida, Katsunori Jinnouchi, Hiroyuki Nishimura, Tomoko Suzuki, Fumio Miyamoto, Keizo Kajiwara & Tomio Jinnouchi. (2018) Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes. Journal of Atherosclerosis and Thrombosis 25:6, pages 467-476.
Crossref
Crossref
Yasuo Terauchi, Masahiro Tamura, Masayuki Senda, Ryoji Gunji & Kohei Kaku. (2018) Long‐term safety and efficacy of tofogliflozin as add‐on to insulin in patients with type 2 diabetes: Results from a 52‐week, multicentre, randomized, double‐blind, open‐label extension, Phase 4 study in Japan (J‐STEP/INS). Diabetes, Obesity and Metabolism 20:5, pages 1176-1185.
Crossref
Crossref
Motoshi Ouchi, Kenzo Oba, Kohei Kaku, Hideki Suganami, Akihiro Yoshida, Yasunori Fukunaka, Promsuk Jutabha, Asuka Morita, Naoyuki Otani, Keitaro Hayashi, Tomoe Fujita, Tatsuya Suzuki, Masahiro Yasutake & Naohiko Anzai. (2018) Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin. Diabetes, Obesity and Metabolism 20:4, pages 1061-1065.
Crossref
Crossref
Kiyohide Nunoi, Yuichi Sato, Kohei Kaku, Akihiro Yoshida & Hideki Suganami. (2018) Effects of sodium-glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes. Endocrinology, Diabetes & Metabolism 1:2, pages e00015.
Crossref
Crossref
Y. Matsubayashi, A. Yoshida, H. Suganami, H. Ishiguro, M. Yamamoto, K. Fujihara, S. Kodama, S. Tanaka, K. Kaku & H. Sone. (2018) Role of fatty liver in the association between obesity and reduced hepatic insulin clearance. Diabetes & Metabolism 44:2, pages 135-142.
Crossref
Crossref
T. Abe, Y. Matsubayashi, A. Yoshida, H. Suganami, T. Nojima, T. Osawa, M. Ishizawa, M. Yamamoto, K. Fujihara, S. Tanaka, K. Kaku & H. Sone. (2018) Predictors of the response of HbA1c and body weight after SGLT2 inhibition. Diabetes & Metabolism 44:2, pages 172-174.
Crossref
Crossref
Shinji Kamei, Masahiro Iwamoto, Miyuki Kameyama, Masashi Shimoda, Tomoe Kinoshita, Atsushi Obata, Tomohiko Kimura, Hidenori Hirukawa, Fuminori Tatsumi, Kenji Kohara, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku & Hideaki Kaneto. (2018) Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus. Journal of Diabetes Research 2018, pages 1-6.
Crossref
Crossref
Kazunori Utsunomiya, Naoki Shimmoto, Masayuki Senda, Yuji Kurihara, Ryoji Gunji, Shoko Fujii, Seigo Kakiuchi, Hisataka Fujiwara, Hiroyuki Kameda, Masahiro Tamura & Kohei Kaku. (2017) Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post-marketing study (J-STEP/EL Study). Journal of Diabetes Investigation 8:6, pages 766-775.
Crossref
Crossref
Yasuo Terauchi, Masahiro Tamura, Masayuki Senda, Ryoji Gunji & Kohei Kaku. (2017) Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial. Diabetes, Obesity and Metabolism 19:10, pages 1397-1407.
Crossref
Crossref
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Yutaka Umayahara, Hideaki Kaneto, Takeshi Osonoi, Tsunehiko Yamamoto, Nobuichi Kuribayashi, Kazuhisa Maeda, Hiroki Yokoyama, Keisuke Kosugi, Kentaro Ohtoshi, Isao Hayashi, Satoru Sumitani, Mamiko Tsugawa, Makoto Ohashi, Hideki Taki, Tadashi Nakamura, Satoshi Kawashima, Yasunori Sato, Hirotaka Watada & Iichiro Shimomura. (2017) Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study. Diabetes Therapy 8:5, pages 999-1013.
Crossref
Crossref
André J. Scheen. (2016) Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes. Clinical Pharmacokinetics 56:7, pages 703-718.
Crossref
Crossref
G. Bebernitz. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
491
511
.
Kazunori Utsunomiya, Naoki Shimmoto, Masayuki Senda, Yuji Kurihara, Ryoji Gunji, Hiroyuki Kameda, Masahiro Tamura, Hanako Mihara & Kohei Kaku. (2016)
Japanese study of tofogliflozin with type 2 diabetes mellitus patients in an observational study of the elderly (J‐
STEP
/
EL
): A 12‐week interim analysis
. Journal of Diabetes Investigation 7:5, pages 755-763.
Crossref
Crossref
Shinji Kobuchi, Megumi Matsuno, Etsuko Fukuda, Yukako Ito & Toshiyuki Sakaeda. (2016) Development and validation of an LC–MS/MS method for the determination of tofogliflozin in plasma and its application to a pharmacokinetic study in rats. Journal of Chromatography B 1027, pages 227-233.
Crossref
Crossref
Shannon R. Hinson, Vanda A. Lennon & Sean J. Pittock. 2016. Autoimmune Neurology. Autoimmune Neurology
377
403
.
Nobuya Inagaki, Maki Goda, Shoko Yokota, Nobuko Maruyama & Hiroaki Iijima. (2015) Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Advances in Therapy 32:11, pages 1085-1103.
Crossref
Crossref
Takashi Kadowaki, Masakazu Haneda, Nobuya Inagaki, Yasuo Terauchi, Atsushi Taniguchi, Kazuki Koiwai, Henning Rattunde, Hans J. Woerle & Uli C. Broedl. (2015) Efficacy and Safety of Empagliflozin Monotherapy for 52 Weeks in Japanese Patients with Type 2 Diabetes: A Randomized, Double-Blind, Parallel-Group Study. Advances in Therapy 32:4, pages 306-318.
Crossref
Crossref
Raewyn M. Poole & Jennifer E. Prossler. (2014) Tofogliflozin: First Global Approval. Drugs 74:8, pages 939-944.
Crossref
Crossref